Form 4: Haemonetics Corp Executive Roy Galvin Reports Stock Transactions

Roy Galvin, President of Global Plasma & BC at Haemonetics Corp, reports disposition of shares to cover tax obligations and acquisition of shares through an employee stock purchase plan.

Summary

• On May 15, 2025, Roy Galvin, President of Global Plasma & BC at Haemonetics Corp, disposed of 201 shares of common stock at a price of $69.38 to cover tax obligations related to vesting restricted stock units.
• On May 16, 2025, Mr. Galvin disposed of 257 shares of common stock at a price of $70.31 also to cover tax obligations related to vesting restricted stock units.
• Following these transactions, Mr. Galvin beneficially owns 7,243 shares, which includes unvested RSUs and 328 shares acquired through the company's Employee Stock Purchase Plan on April 30, 2025.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to executive compensation and does not indicate any significant positive or negative sentiment.

Positives

• Mr. Galvin acquired 328 shares through the Employee Stock Purchase Plan on April 30, 2025, indicating confidence in the company.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders.

Key Dates

Keywords

Form 4, Beneficial Ownership, HAEMONETICS CORP, HAE, Roy Galvin, Stock Transaction, Employee Stock Purchase Plan, Restricted Stock Units, Tax Obligations